Ktov + Ktovw ** Broke 200ma FDA News Watch for reaponse to phase 3 drug “kit-302” NDA filed in july !
On July 31, 2017, Kitov Pharmaceuticals Holdings Ltd. (the “Company”) announced that it had submitted a New Drug Application to the U.S. Food and Drug Administration for KIT-302, its lead drug candidate. On July 31, 2017, the Company issued a press release in connection with its submission of the New Drug Application, “ Kitov Submits New Drug Application to FDA for KIT-302 ”, which is attached hereto as Exhibit 99.1
Market Data 
Markets 
AI
